Health Technology · Pharmaceuticals: Major · NSE: AHCL · data 2026-10-09
Anlon Healthcare Limited
Health check: Strong (7.8/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹28.11
Market cap
₹1,428 cr
P/E
47.2
P/B
—
ROE
18.4%
ROCE
24.3%
Debt / equity
0.19
Dividend yield
0.00%
1-year return
128.2%
52-week high
₹37.24
52-week low
₹10.37
Operating margin
24.2%
Growth
| Revenue (last 12 months) | ₹226 cr |
| Net profit (last 12 months) | ₹32 cr |
| Sales growth, 3 years (yearly) | 15.1% |
| Profit growth, 3 years (yearly) | 69.8% |
Shareholding (2026-06-30)
| Promoters | 52.68% |
| Foreign institutions (FII) | 1.67% |
| Domestic institutions (DII) | 1.22% |
| Public | 47.32% |
| Promoter shares pledged | 0.00% |
| Number of shareholders | 34,671 |
Similar companies
Hester Biosciences Limited (HESTERBIO) · Accent Microcell Limited (ACCENTMIC) · TTK Healthcare Limited (TTKHLTCARE) · Bharat Parenterals Ltd. (BPLPHARMA) · Kopran Limited (KOPRAN)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open AHCL in NSE Scanner →